Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study

IntroductionThe treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatinib (an antiangiogenic agent) for patients with r/r...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yanfei Liu, Yuqin Song, Shubo Zuo, Xian Zhang, Hui Liu, Jingwen Wang, Jingbo Wang, Yongjing Tang, Wen Zheng, Zhitao Ying, Lingyan Ping, Chen Zhang, Meng Wu, Jun Zhu, Yan Xie
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-04-01
Col·lecció:	Frontiers in Immunology
Matèries:	peripheral T-cell lymphoma PD-1 inhibitor apatinib immunotherapy camrelizumab
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1128172/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!